Chinese COVID vaccine candidate based on inactivated virus appears safe, induces immune response, study finds – Medical Xpress

Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published today in The Lancet Infectious Diseases journal, finding the formulation appears safe and induces an antibody response in healthy volunteers aged 18 to 59 years.
Antibody responses could be induced within 28 days of the first immunisation, by giving two doses of the vaccine candidate 14 days apart.
The study also identifies the optimum dose…

Click here to view the original article.